All these early entrant institutions need (and want) are the the calendar to get to July 1 with TLD/journal announcements and significant projected revenue from the Specials Program validated by Advent and Charles River Lab production projections after that time if possible and then it’s off to the races. This is why the attempt is on now to get back quickly to $.38 before the run up. Advent and Charles River Labs can validate an uptick in cell therapy demand perhaps by the time of their Q2 reports if PIM funding is released to UK patients this month. Those trying for a last minute bargain are meeting resistance as volume has dried up and at some point someone will very likely jump in big before July 1 in anticipation of this action leaving some to speculate that there has been some sort of leak ; ). Decided to go back to my old way of looking at things and reporting rather than just sit around in the wait mode today. Hope this helps someone understand the dynamics at work here a little better. Best wishes.
Market Data 
Markets 
